DRUG — Bright Minds Biosciences Inc. stock price, charts and financials

Latest market price

80.45

+1.12+1.41%

Overview Short InterestFilings

DRUGQT81Bright Minds Biosciences Inc.·NASDAQ

Overview Short InterestFilings

80.45+1.41%

News

Up 1.4% — Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 97.4%: Read This Before Placing a Bet (zacks.com).

Medium confidence

Loading chart...

Screen all →

AUPH-2.33%$15.48 MESO+4.23%$16.61 ZBIO-0.58%$32.24 GHRS-1.72%$29.75 TSHA-1.45%$6.46 STOK-1.44%$32.24 ABCL+36.08%$9.43 VRDN-2.67%$22.96

Snapshot

Index	-	P/E	-	EPS (ttm)	-	Insider Own	10.82%	Shs Outstand	9.79M	Perf Week	8.29%

Market Cap	779.70M	Forward P/E	-	EPS next Y	-8.92	Insider Trans	-10.32%	Shs Float	6.11M	Perf Month	1.45%

Enterprise Value	558.38M	PEG	0.30	EPS next Q	-	Inst Own	-	Short Float	15.65%	Perf Quarter	-10.68%

Income	-20.12M	P/S	0.00	EPS this Y	-	Inst Trans	-	Short Ratio	3.11	Perf Half Y	8.55%

Sales	0.00	P/B	3.46	EPS next Y	-88.26%	ROA	-8.83%	Short Interest	955.80K	Perf YTD	1.65%

Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-20.73%	52W High	125.49 -35.89%	Perf Year	122.90%

Cash/sh	-	P/FCF	-	EPS past 3/5Y	-	ROIC	-10.20%	52W Low	34.67 132.03%	Perf 3Y	1918.58%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-	Gross Margin	0.00%	Volatility	5.26% 5.60%	Perf 5Y	236.86%

Dividend TTM	-	EV/Sales	0.00	EPS Y/Y TTM	-303.89%	Oper. Margin	0.00%	ATR (14)	4.35	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	81.48	Sales Y/Y TTM	-	Profit Margin	0.00%	RSI (14)	60.13	Recom	2.00

Dividend Gr. 3/5Y	-	Current Ratio	81.48	EPS Q/Q	-	SMA20	5.75%	Beta	-4.50	Target Price	145.00

Payout	0.00%	Debt/Eq	0.00	Sales Q/Q	-	SMA50	11.27%	Rel Volume	0.50	Prev Close	79.33

Employees	26	LT Debt/Eq	-	Earnings	Aug 13	SMA200	4.37%	Avg Volume	313.91K	Price	80.45

IPO Date	Mar 22, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	17.84% -	Net Debt/EBITDA	9.85	Volume	156,403	Change	1.41%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jun-01-26	Reiterated	HC Wainwright & Co.	Buy	$85 → $145
May-20-26	Reiterated	Piper Sandler	Overweight	$220
Feb-13-26	Reiterated	Robert W. Baird		$142 → $126
Jan-07-26	Reiterated	Robert W. Baird		$82 → $142
Jan-07-26	Reiterated	BTIG	Buy	$147
Jan-06-26	Reiterated	BTIG	Buy	$147
May-07-25	Initiated	Chardan	Buy	$80
Jan-10-25	Initiated	H.C	Buy	$85

Latest News

Today

Today10:57AM

Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 97.4%: Read This Before Placing a Betzacks.com

Jul-31-26

Jul-31-2608:30AM

Vistagen Appoints Douglas J. Williamson to its Board of Directorsglobenewswire.com

Jul-23-26

Jul-23-2610:56AM

Wall Street Analysts See a 107.53% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High?zacks.com

Jul-22-26

Jul-22-2601:02PM

All You Need to Know About Bright Minds Biosciences Inc. (DRUG) Rating Upgrade to Strong Buyzacks.com

Company

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company’s BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	FY 2025 9/30/2025	FY 2024 9/30/2024	FY 2023 9/30/2023	FY 2022 9/30/2022	FY 2021 9/30/2021	FY 2020 9/30/2020	FY 2019 9/30/2019
Total Revenue	0	0	0	—	—	—	—
Cost of Goods Sold Incl. D&A	0	0	0	—	—	—	—
Gross Profit	0	0	0	—	—	—	—
Selling, General and Administrative Excl. Other	2	1	2	—	—	—	—
Research and Development	8	1	4	—	—	—	—
Other Operating Expense	0	0	-1	—	—	—	—
Operating Income	-10	-2	-5	—	—	—	—
Interest Expense	0	0	0	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—
Non-Operating Income (Expense)	1	0	0	—	—	—	—
Net Income Before Taxes	-9	-2	-5	—	—	—	—
Income Taxes	0	0	0	—	—	—	—
Consolidated Net Income	-9	-2	-5	—	—	—	—
Net Income From Continuing Operations	-9	-2	-5	—	—	—	—
Net Income	-9	-2	-5	—	—	—	—
EPS (Recurring)	-1.27	-0.48	-1.47	—	—	—	—
EPS (Basic, Before Extraordinaries)	-1.27	-0.48	-1.47	—	—	—	—
EPS (Diluted)	-1.27	-0.48	-1.47	—	—	—	—
EBITDA	-9	-2	-5	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—
Price To Sales Ratio	—	—	—	—	—	—	—
Gross Margin	—	—	—	—	—	—	—
Operating Margin	—	—	—	—	—	—	—
Net Margin	—	—	—	—	—	—	—
Shares Outstanding	7	4	4	—	—	—	—
Market Capitalization	425	5	6	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cormorant Asset Management, LP	other: Former 10% Owner	Apr 28 '26	Sale	89.50	109,331	9,785,125	950,000	Apr 30
Cormorant Asset Management, LP	10% Owner	Nov 04 '24	Buy	21.70	184,331	3,999,983	1,059,331	Nov 06
Cormorant Asset Management, LP	10% Owner	Oct 16 '24	Buy	23.46	50,000	1,172,814	875,000	Oct 17
Cormorant Asset Management, LP	10% Owner	Oct 15 '24	Buy	5.53	372,591	2,061,573	825,000	Oct 17

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.